Annual report pursuant to Section 13 and 15(d)

Note 4 - Acquisitions (Details Textual)

v3.19.2
Note 4 - Acquisitions (Details Textual) - USD ($)
$ in Thousands
11 Months Ended 12 Months Ended
Jun. 30, 2019
Jun. 04, 2019
Aug. 01, 2018
Jul. 02, 2018
Feb. 01, 2018
Jan. 02, 2018
Sep. 05, 2017
Aug. 01, 2016
Jul. 01, 2016
Jun. 30, 2019
Jun. 30, 2019
Jun. 30, 2019
Jun. 30, 2019
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2017
Payments to Acquire Businesses, Net of Cash Acquired, Total                       $ 289,492     $ 67,851 $ 253,785
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability                           (26,600) $ (11,800)
Business Combination, Contingent Consideration, Liability, Total $ 12,600                 $ 12,600 $ 12,600 12,600 $ 12,600 $ 12,600  
QT Holdings Corporation [Member]                                
Payments to Acquire Businesses, Net of Cash Acquired, Total       $ 20,404                   20,462    
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 51,000     51,000           51,000 51,000 51,000 51,000 51,000    
Business Acquisition, Goodwill, Expected Tax Deductible Amount       0                        
Goodwill, Purchase Accounting Adjustments                         4,700 4,691    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 12,256     20,000           12,256 12,256 12,256 12,256 12,256    
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles                           (7,744)    
Business Combination, Consideration Transferred, Total       25,604                   25,762    
Business Combination, Consideration Transferred, Liabilities Incurred       $ 5,200                   5,300    
QT Holdings Corporation [Member] | Developed Technology Rights [Member]                                
Finite-Lived Intangible Asset, Useful Life       14 years                        
Exosome Diagnostics, Inc [Member]                                
Payments to Acquire Businesses, Net of Cash Acquired, Total 251,623   $ 251,825             251,600            
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 325,000   325,000             325,000 325,000 $ 325,000 325,000 325,000    
Business Acquisition, Goodwill, Expected Tax Deductible Amount     0                          
Goodwill, Purchase Accounting Adjustments                     8,770          
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability                     2,000          
Business Combination, Consideration Transferred, Total     253,625               255,423          
Business Combination, Consideration Transferred, Liabilities Incurred     1,800               3,800          
Exosome Diagnostics, Inc [Member] | Calendar Year 2020 EBITA Between $45 Million and $58 Million or Greater [Member]                                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High     250,000                          
Exosome Diagnostics, Inc [Member] | Calendar Year 2022 EBITA for A New Instrument Product Between $54 Million and $70 Million or Greater [Member]                                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High     45,000                          
Exosome Diagnostics, Inc [Member] | Calendar Year 2022 EBITA for Remaining Business Between $150 Million and $190 Million or Greater [Member]                                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High     30,000                          
Exosome Diagnostics, Inc [Member] | Developed Technology Rights [Member]                                
Finite-Lived Intangible Asset, Useful Life                       15 years        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles     180,000                          
Exosome Diagnostics, Inc [Member] | Trade Names [Member]                                
Finite-Lived Intangible Asset, Useful Life                       15 years        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 58,000               58,000 58,000 $ 58,000 58,000 58,000    
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles                     58,000          
Exosome Diagnostics, Inc [Member] | Developed Technology [Member]                                
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 105,000                 105,000 105,000 $ 105,000 105,000 105,000    
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles                     (75,000)          
Exosome Diagnostics, Inc [Member] | Customer Relationships [Member]                                
Finite-Lived Intangible Asset, Useful Life                       14 years        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 2,300               2,300 2,300 $ 2,300 2,300 2,300    
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles                     2,300          
B-MoGen [Member]                                
Payments to Acquire Businesses, Net of Cash Acquired, Total   $ 17,448                            
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $ 38,000 38,000               $ 38,000 $ 38,000 38,000 $ 38,000 $ 38,000    
Business Acquisition, Goodwill, Expected Tax Deductible Amount   0                            
Business Combination, Step Acquisition, Equity Interest in Acquiree, Before Remeasurement to Fair Value   1,400                            
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain   3,700                            
Business Combination, Consideration Transferred, Liabilities Incurred   $ 5,500                            
B-MoGen [Member] | Developed Technology Rights [Member]                                
Finite-Lived Intangible Asset, Useful Life   14 years                            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles   $ 14,000                            
B-MoGen [Member] | Customer Relationships [Member]                                
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles   $ 400                            
Trevigen Inc. [Member]                                
Payments to Acquire Businesses, Net of Cash Acquired, Total             $ 10,600         10,644        
Business Acquisition, Goodwill, Expected Tax Deductible Amount             $ 0                  
Business Combination, Consideration Transferred, Total                       10,644        
Business Combination, Consideration Transferred, Liabilities Incurred                              
Atlanta Biologicals [Member]                                
Payments to Acquire Businesses, Net of Cash Acquired, Total                       51,274        
Business Acquisition, Goodwill, Expected Tax Deductible Amount           $ 0                    
Business Combination, Consideration Transferred, Total           $ 51,300           51,274        
Business Combination, Consideration Transferred, Liabilities Incurred                              
Atlanta Biologicals [Member] | Developed Technology Rights [Member]                                
Finite-Lived Intangible Asset, Useful Life           13 years                    
Atlanta Biologicals [Member] | Trade Names [Member]                                
Finite-Lived Intangible Asset, Useful Life           15 years                    
Atlanta Biologicals [Member] | Customer Relationships [Member]                                
Finite-Lived Intangible Asset, Useful Life           12 years                    
Eurocell Diagnostics, SAS [Member]                                
Payments to Acquire Businesses, Net of Cash Acquired, Total                       5,933        
Business Acquisition, Goodwill, Expected Tax Deductible Amount         $ 0                      
Business Combination, Consideration Transferred, Total         7,300             7,329        
Payments to Acquire Businesses, Gross         6,000                      
Business Combination, Consideration Transferred, Liabilities Incurred         $ 1,300             1,396        
Eurocell Diagnostics, SAS [Member] | Customer Relationships [Member]                                
Finite-Lived Intangible Asset, Useful Life         7 years                      
Advanced Cell Diagnostics (ACD) [Member]                                
Payments to Acquire Businesses, Net of Cash Acquired, Total               $ 247,000       247,038        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High               75,000                
Business Acquisition, Goodwill, Expected Tax Deductible Amount               0                
Business Combination, Consideration Transferred, Total                       287,638        
Payments to Acquire Businesses, Gross               258,000                
Business Combination, Consideration Transferred, Liabilities Incurred               $ 11,000       3,600        
Business Combination, Consideration Transferred, Employee Vesting Period               1 year 180 days                
Advanced Cell Diagnostics (ACD) [Member] | Pre-acquisition Services [Member]                                
Business Combination, Consideration Transferred, Liabilities Incurred               $ 3,600                
Advanced Cell Diagnostics (ACD) [Member] | Future Services [Member]                                
Business Combination, Consideration Transferred, Liabilities Incurred               7,400                
Advanced Cell Diagnostics (ACD) [Member] | The 2016 Revenue Equal or Exceed $30 Milliom [Member]                                
Business Combination, Contingent Consideration, Liability, Total               25,000                
Business Combination, Contingent Consideration, Liability, Trigger Amount of Revenue               30,000                
Advanced Cell Diagnostics (ACD) [Member] | The 2017 Revenues Equal or Exceed $45 Million [Member]                                
Business Combination, Contingent Consideration, Liability, Total               50,000                
Business Combination, Contingent Consideration, Liability, Trigger Amount of Revenue               $ 45,000                
Space [Member]                                
Payments to Acquire Businesses, Net of Cash Acquired, Total                 $ 6,700     6,747        
Business Acquisition, Goodwill, Expected Tax Deductible Amount                 0              
Business Combination, Consideration Transferred, Total                       9,003        
Payments to Acquire Businesses, Gross                 9,000              
Business Combination, Consideration Transferred, Liabilities Incurred                 $ 2,300     $ 2,256